AAN 2023: DNL343 is safe, appears to work as intended in Phase 1...
Apr 26, 2023 · “DNL343 is generally safe and well-tolerated at doses that demonstrate robust inhibition of ISR,” the researchers concluded, adding that these data “support further …
Sean M. Healey & AMG Center Announces Topline Results in …
About DNL343 . DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR). The ISR appears to be overactive in ALS, …
ALS investigational therapies DNL343 and fosigotifator fail …
Jan 9, 2025 · The investigational oral therapies DNL343 and fosigotifator didn’t significantly slow disease progression in people with amyotrophic lateral sclerosis (ALS) compared with a …
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in …
Dec 5, 2022 · By inhibiting the ISR pathway, DNL343 is intended to prevent or slow disease progression associated with stress granule formation and TDP-43 aggregation, a hallmark …
Denali slides after ALS drug flunks clinical test | pharmaphorum
2 days ago · The South San Francisco biotech announced that eIF2B agonist DNL343 was unable to slow disease progression or increase survival compared to placebo at 24 weeks in …
DNL343 Falls Short of Primary End Point in Phase 2/3 HEALEY-ALS ...
Jan 7, 2025 · Newly announced data from the phase 2/3 HEALEY-ALS Platform trial revealed that DNL343 (Denali Therapeutics), an investigational eIF2B agonist in development for …
Novel small molecule for ALS fails to meet primary endpoint in
Jan 8, 2025 · According to a press release from Denali Therapeutics Inc., the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was …
DNL343 to be Assessed in HEALEY ALS Platform Trial Following …
Dec 6, 2022 · Newly announced interim results from a phase 1b study of Denali Therapeutics’ eIF2B agonist DNL343 showed that the agent was well tolerated and demonstrated robust …
Denali Therapeutics’ trial of DNL343 fails to meet primary endpoint
Jan 7, 2025 · US-based biotechnology company Denali Therapeutics has reported that a Phase II/III trial of DNL343 for amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. …
Patient enrollment complete in DNL343 arm of HEALEY ALS trial
May 14, 2024 · DNL343 becomes the seventh treatment regimen to be fully enrolled since the launch of HEALEY ALS in 2020. The sixth arm of the trial, testing ABBV-CLS-7262 — an …